Lisa S. Rolczynski

Medicine · Health Sciences

5h-index467citations33works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(32), Neuroblastoma Research and Treatments(11), Immune Cell Function and Interaction(6), Immunotherapy and Immune Responses(5), Virus-based gene therapy research(3)

Publications33 total

Supplemental Figure 2 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 4 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 3 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Data from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure Legends from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 4 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 1 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 3 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Data from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 1 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 2 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure Legends from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8<sup>+</sup> CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
2023Open Access
Supplemental Figure 1 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
supplemental legend from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
Supplemental Figure 2 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
Data from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
Supplemental Figure 4 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
Supplemental Figure 3 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
Supplemental Figure 3 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
Supplemental Figure 2 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Adam Johnson(32), Cindy A. Chang(32), Michael C. Jensen(32), Annette Künkele(31), Agne Taraseviciute(18), Olivia Finney(18), Stephanie Mgebroff(18), Julie R. Park(18), Laura S. Finn(17), Carolina Berger(17), Michael F. Berger(16), Virginia J. Hoglund(14), Karen S. Kelly‐Spratt(13), Christopher Brown(6), Christopher Brown(6), Christopher A. Brown(4), Christopher Brown(2), Michael Berger(1), Ali C. Ravanpay(1), Juliane Gust(1)